BioCentury
ARTICLE | Financial News

RA Capital leads Eidos' $64M series B round

April 5, 2018 3:49 PM UTC

Eidos Therapeutics Inc. (San Francisco, Calif.) raised a $64 million series B round led by new investor RA Capital. Eidos' parent company, BridgeBio Pharma LLC (Palo Alto, Calif.), also participated, as did new investors Janus Henderson, Viking Global Investors, Aisling Capital, Perceptive Advisors, Cormorant Asset Management and Amzak Health Investors.

Eidos has raised a total of about $91 million. VP of Business Development and Operations Cameron Turtle told BioCentury the new round will give Eidos runway through launch of a Phase III trial of lead compound AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy. The company plans to begin dosing this month in Phase II trials for the same indication. AG10 is a small molecule targeting TTR in the blood...